GA
HRMY icon

GoalVest Advisory’s Harmony Biosciences HRMY Stock Holding History

GoalVest Advisory’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-68
Closed -$2.23K – 423
2023
Q3 		$2.23K Sell
68
-2
-3% -$69 ﹤0.01% 416
2023
Q2 		$2.46K Buy
+70
New +$2.42K ﹤0.01% 341

Other funds holding HRMY

VM
Valor Management Chicago, Illinois $181M AUM 6.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

GoalVest Advisory's HRMY Position: Q4 2023 in Review

GoalVest Advisory sold out of Harmony Biosciences (HRMY) in Q4 2023, closing a stake of 68 shares — an estimated $2.23K sold.

GoalVest Advisory first reported a position in HRMY in Q2 2023 and held it in 2 quarters. The position peaked at $2.46K in Q2 2023. 221 funds tracked by Wall St. Rank hold HRMY as of Q4 2023.

  • GoalVest Advisory reported no remaining Harmony Biosciences position as of Q4 2023 after selling out during the quarter.
  • GoalVest Advisory sold 68 Harmony Biosciences shares in Q4 2023, an estimated $2.23K.
  • GoalVest Advisory first reported a position in Harmony Biosciences in Q2 2023 and held it in 2 quarters.
  • GoalVest Advisory's Harmony Biosciences position peaked at $2.46K in Q2 2023.
  • 221 funds tracked by Wall St. Rank held Harmony Biosciences as of Q4 2023.

Based on GoalVest Advisory's 13F filing for Q4 2023, filed 2 Jan 2024.